87 related articles for article (PubMed ID: 21566404)
1. [Significance of A20 in B-cell lymphomas].
Kato M; Ogawa S
Rinsho Ketsueki; 2011 Apr; 52(4):190-7. PubMed ID: 21566404
[No Abstract] [Full Text] [Related]
2. Frequent inactivation of A20 through gene mutation in B-cell lymphomas.
Kato M; Sanada M; Kato I; Sato Y; Takita J; Takeuchi K; Niwa A; Chen Y; Nakazaki K; Nomoto J; Asakura Y; Akatsuka M; Hayashi Y; Mori H; Igarashi T; Kurokawa M; Chiba S; Mori S; Ishikawa Y; Okamoto K; Tobinai K; Nakagama H; Nakahata T; Yoshino T; Kobayashi Y; Ogawa S
Rinsho Ketsueki; 2011 Jun; 52(6):313-9. PubMed ID: 21737982
[No Abstract] [Full Text] [Related]
3. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Honma K; Tsuzuki S; Nakagawa M; Tagawa H; Nakamura S; Morishima Y; Seto M
Blood; 2009 Sep; 114(12):2467-75. PubMed ID: 19608751
[TBL] [Abstract][Full Text] [Related]
4. A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme.
Malynn BA; Ma A
J Exp Med; 2009 May; 206(5):977-80. PubMed ID: 19380636
[TBL] [Abstract][Full Text] [Related]
5. Expression, biological activities and mechanisms of action of A20 (TNFAIP3).
Verstrepen L; Verhelst K; van Loo G; Carpentier I; Ley SC; Beyaert R
Biochem Pharmacol; 2010 Dec; 80(12):2009-20. PubMed ID: 20599425
[TBL] [Abstract][Full Text] [Related]
6. Frequent inactivation of A20 in B-cell lymphomas.
Kato M; Sanada M; Kato I; Sato Y; Takita J; Takeuchi K; Niwa A; Chen Y; Nakazaki K; Nomoto J; Asakura Y; Muto S; Tamura A; Iio M; Akatsuka Y; Hayashi Y; Mori H; Igarashi T; Kurokawa M; Chiba S; Mori S; Ishikawa Y; Okamoto K; Tobinai K; Nakagama H; Nakahata T; Yoshino T; Kobayashi Y; Ogawa S
Nature; 2009 Jun; 459(7247):712-6. PubMed ID: 19412163
[TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of A20 prevents cardiac cell death and myocardial dysfunction after myocardial infarction.
Shaw J; Eydelnant IA; Kirshenbaum LA
Circulation; 2007 Apr; 115(14):1827-9. PubMed ID: 17420361
[No Abstract] [Full Text] [Related]
8. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R
J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639
[TBL] [Abstract][Full Text] [Related]
9. A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.
Giulino L; Mathew S; Ballon G; Chadburn A; Barouk S; Antonicelli G; Leoncini L; Liu YF; Gogineni S; Tam W; Cesarman E
Blood; 2011 May; 117(18):4852-4. PubMed ID: 21406721
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL.
Philipp C; Edelmann J; Bühler A; Winkler D; Stilgenbauer S; Küppers R
Int J Cancer; 2011 Apr; 128(7):1747-50. PubMed ID: 20533286
[TBL] [Abstract][Full Text] [Related]
11. Intron-derived aberrant splicing of A20 transcript in rheumatoid arthritis.
Yoon HK; Byun HS; Lee H; Jeon J; Lee Y; Li Y; Jin EH; Kim J; Hong JH; Kim JH; Seok JH; Kang SW; Lee WH; Hur GM
Rheumatology (Oxford); 2013 Mar; 52(3):427-37. PubMed ID: 23148088
[TBL] [Abstract][Full Text] [Related]
12. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease.
Vereecke L; Beyaert R; van Loo G
Biochem Soc Trans; 2011 Aug; 39(4):1086-91. PubMed ID: 21787353
[TBL] [Abstract][Full Text] [Related]
13. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma.
Chanudet E; Huang Y; Ichimura K; Dong G; Hamoudi RA; Radford J; Wotherspoon AC; Isaacson PG; Ferry J; Du MQ
Leukemia; 2010 Feb; 24(2):483-7. PubMed ID: 19907439
[No Abstract] [Full Text] [Related]
14. Regulation of NF-κB signaling by the A20 deubiquitinase.
Shembade N; Harhaj EW
Cell Mol Immunol; 2012 Mar; 9(2):123-30. PubMed ID: 22343828
[TBL] [Abstract][Full Text] [Related]
15. A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology.
Hirsch B; Grünbaum M; Wagner F; Bi Y; Lucka L; Du MQ; Stein H; Dürkop H
Histopathology; 2012 May; 60(6B):E19-27. PubMed ID: 22393903
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
[TBL] [Abstract][Full Text] [Related]
17. A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.
Stilo R; Varricchio E; Liguoro D; Leonardi A; Vito P
J Cell Sci; 2008 Apr; 121(Pt 8):1165-71. PubMed ID: 18349075
[TBL] [Abstract][Full Text] [Related]
18. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F
Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598
[TBL] [Abstract][Full Text] [Related]
19. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands.
Chanudet E; Ye H; Ferry J; Bacon CM; Adam P; Müller-Hermelink HK; Radford J; Pileri SA; Ichimura K; Collins VP; Hamoudi RA; Nicholson AG; Wotherspoon AC; Isaacson PG; Du MQ
J Pathol; 2009 Feb; 217(3):420-30. PubMed ID: 19006194
[TBL] [Abstract][Full Text] [Related]
20. RNF11, a new piece in the A20 puzzle.
Jacque E; Ley SC
EMBO J; 2009 Mar; 28(5):455-6. PubMed ID: 19262463
[No Abstract] [Full Text] [Related]
[Next] [New Search]
